{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:11:04Z","timestamp":1790637064799,"version":"4.1.0"},"reference-count":16,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>A new drug, trans sodium crocetinate (TSC), has been developed to enhance the delivery of oxygen to hypoxic tissues. Cancerous tumors, such as glioblastoma multiforme (GBM), are very hypoxic, and it has been suggested that radiation therapy (RT) is more beneficial if tumors are better oxygenated. A Phase I\/II clinical trial was conducted to determine the effect of adding TSC to RT sessions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      An open, single-arm clinical trial incorporating the standard of care (SOC) for GBM was conducted at 18 clinical sites. There were 6 weeks of RT consisting of 2 Gy\/day for 5 days\/week, beginning after an initial resection or stereotactic biopsy to confirm GBM. Temozolomide (TMZ), 75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , was given before each RT session. The TSC, 0.25 mg\/kg, was intravenously administered around 45 minutes before an RT session 3 days\/week, usually on Monday, Wednesday, and Friday.\n                    <\/jats:p>\n                    <jats:p>A Phase I run-in period included 2 cohorts. The first cohort contained 3 patients who were given a half dose of the intravenous TSC (that is, 0.25 mg\/kg, 3 times per week for only the first 3 weeks of RT). After a Safety Monitoring Committee (SMC) had verified that no dose-limiting toxicity (DLT) had occurred, a second cohort of 6 patients was given the same dosage of TSC but for the full 6 weeks of RT. After the SMC verified that no DLTs had occurred, Phase II began, with the administration of the full 18 doses of TSC. Fifty additional patients were enrolled during Phase II.<\/jats:p>\n                    <jats:p>\n                      Following the completion of RT, the patients rested for a month. After that, SOC TMZ chemotherapy (150\u2013200 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) was administered for 5 days of the 1st week of 6 monthly cycles. No TSC was administered during this chemotherapy phase or later in the trial. Any other follow-up therapies were administered at the discretion of the individual investigators.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Kaplan-Meier analysis showed that 36% of the full-dose TSC patients were alive at 2 years, compared with historical survival values ranging from 27% to 30% for the SOC. Survival for the biopsy-only subset of patients was 40%, as compared with 42.9% for those patients having a complete resection before treatment. In addition, 2 of the 3 Phase I, Cohort 1 patients survived at 2 years. Contrast MRI data suggested that considerable pseudoprogression had occurred. Both Karnofsky Performance Status (KPS) scores and quality of life (QOL) questionnaires indicated that a good quality of life existed for most patients throughout the trial. No serious adverse events occurring in the trial were attributed to TSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>This trial contained a single arm consisting of 59 patients. The results strongly suggested that adding TSC during RT is beneficial for the treatment of GBM. Trans sodium crocetinate offers a novel, easily implemented way to combat hypoxia in tumor tissue.<\/jats:p>\n                    <jats:p>\n                      Clinical trial registration no.: NCT01465347 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2016.3.jns152693","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T11:01:36Z","timestamp":1463137296000},"page":"460-466","source":"Crossref","is-referenced-by-count":39,"title":["Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme"],"prefix":"10.3171","volume":"126","author":[{"given":"John L.","family":"Gainer","sequence":"first","affiliation":[{"name":"Diffusion Pharmaceuticals LLC;\u00a0"},{"name":"University of Virginia, Charlottesville, Virginia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P.","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Departments of Neurological Surgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Larner","sequence":"additional","affiliation":[{"name":"Radiation Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[{"name":"Diffusion Pharmaceuticals LLC;\u00a0"},{"name":"Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-jns152693","series-title":"Curr Neurol Neurosci Rep","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11910-014-0517-x","article-title":"The value of extent of resection of glioblastomas: clinical evidence and current approach","volume":"15","author":"Almeida JP,","year":"2015","unstructured":"Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A: The value of extent of resection of glioblastomas: clinical evidence and current approach. Curr Neurol Neurosci Rep 15:517, 201510.1007\/s11910-014-0517-x25467408"},{"key":"b2-jns152693","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot OL,","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, : Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722, 201410.1056\/NEJMoa130834524552318"},{"key":"b3-jns152693","series-title":"Expert Opin Investig Drugs","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1517\/13543784.17.6.917","article-title":"Trans-sodium crocetinate for treating hypoxia\/ischemia","volume":"17","author":"Gainer JL:","year":"2008","unstructured":"Gainer JL: Trans-sodium crocetinate for treating hypoxia\/ischemia. Expert Opin Investig Drugs 17:917\u2013924, 20081849199210.1517\/13543784.17.6.917"},{"key":"b4-jns152693","series-title":"Clin Exp Pharmacol","first-page":"103","article-title":"Increasing oxygen in hypoxic tumors","volume":"1","author":"Gainer JL,","year":"2011","unstructured":"Gainer JL, Lankford MF: Increasing oxygen in hypoxic tumors. Clin Exp Pharmacol 1:103, 2011"},{"key":"b5-jns152693","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert MR,","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, : A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708, 201410.1056\/NEJMoa130857324552317"},{"key":"b6-jns152693","series-title":"Respir Physiol","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0034-5687(85)90020-9","article-title":"Kinetics of O2 uptake and release by red cells in stopped-flow apparatus: effects of unstirred layer","volume":"59","author":"Holland RAB,","year":"1985","unstructured":"Holland RAB, Shibata H, Scheid P, Piiper J: Kinetics of O2 uptake and release by red cells in stopped-flow apparatus: effects of unstirred layer. Respir Physiol 59:71\u201391, 198510.1016\/0034-5687(85)90020-93975504"},{"key":"b7-jns152693","series-title":"Water Structure and Science","author":"London South Bank University","unstructured":"London South Bank University: Water Structure and Science (http:\/\/www1.lsbu.ac.uk\/water\/kosmotropes_chaotropes.html) [Accessed March 18, 2016]"},{"key":"b8-jns152693","series-title":"Vasc Med","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/1358863X11422742","article-title":"Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication","volume":"16","author":"Mohler ER III,","year":"2011","unstructured":"Mohler ER III, Gainer JL, Whitten K, Eraso LH, Thanaporn PK, Bauer T: Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication. Vasc Med 16:346\u2013353, 20112200300010.1177\/1358863X11422742"},{"key":"b9-jns152693","series-title":"Shock","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00024382-199809000-00010","article-title":"A novel fluid resuscitation therapy for hemorrhagic shock","volume":"10","author":"Roy JW,","year":"1998","unstructured":"Roy JW, Graham MC, Griffin AM, Gainer JL: A novel fluid resuscitation therapy for hemorrhagic shock. Shock 10:213\u2013217, 1998974465010.1097\/00024382-199809000-00010"},{"key":"b10-jns152693","series-title":"Neurol Med Chir (Tokyo)","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2176\/nmc.oa2012-0441","article-title":"Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study","volume":"54","author":"Saito K,","year":"2014","unstructured":"Saito K, Mukasa A, Narita Y, Tabei Y, Shinoura N, Shibui S, : Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. Neurol Med Chir (Tokyo) 54:272\u2013279, 20142425750210.2176\/nmc.oa2012-0441"},{"key":"b11-jns152693","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3171\/2009.11.JNS091314","article-title":"Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide","volume":"113","author":"Sheehan J,","year":"2010","unstructured":"Sheehan J, Cifarelli CP, Dassoulas K, Olson C, Rainey J, Han S: Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide. J Neurosurg 113:234\u2013239, 201010.3171\/2009.11.JNS09131420001586"},{"key":"b12-jns152693","series-title":"Future Oncol","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2217\/fon.10.123","article-title":"Improving the radiosensitivity of radioresistant and hypoxic glioblastoma","volume":"6","author":"Sheehan JP,","year":"2010","unstructured":"Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM: Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol 6:1591\u20131601, 201010.2217\/fon.10.12321062158"},{"key":"b13-jns152693","series-title":"J Phys Chem B","doi-asserted-by":"publisher","first-page":"18078","DOI":"10.1021\/jp064308+","article-title":"Trans-sodium crocetinate and diffusion enhancement","volume":"110","author":"Stennett AK,","year":"2006","unstructured":"Stennett AK, Dempsey GL, Gainer JL: Trans-sodium crocetinate and diffusion enhancement. J Phys Chem B 110:18078\u201318080, 20061697041310.1021\/jp064308+"},{"key":"b14-jns152693","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R,","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996, 20051575800910.1056\/NEJMoa043330"},{"key":"b15-jns152693","series-title":"Eur J Neurol","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/ene.12192","article-title":"Defining pseudoprogression in glioblastoma multiforme","volume":"20","author":"Van Mieghem E,","year":"2013","unstructured":"Van Mieghem E, Wozniak A, Geussens Y, Menten J, De Vleeschouwer S, Van Calenbergh F, : Defining pseudoprogression in glioblastoma multiforme. Eur J Neurol 20:1335\u20131341, 201310.1111\/ene.12192"},{"key":"b16-jns152693","series-title":"J Appl Physiol (1985)","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1152\/jappl.1985.58.4.1215","article-title":"Kinetics of O2 uptake and release by human erythrocytes studied by a stopped-flow technique","volume":"58","author":"Yamaguchi K,","year":"1985","unstructured":"Yamaguchi K, Nguyen-Phu D, Scheid P, Piiper J: Kinetics of O2 uptake and release by human erythrocytes studied by a stopped-flow technique. J Appl Physiol (1985) 58:1215\u20131224, 1985398867710.1152\/jappl.1985.58.4.1215"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/126\/2\/article-p460.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/126\/2\/article-p460.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/126\/2\/article-p460.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T23:02:11Z","timestamp":1742684531000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/126\/2\/article-p460.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":16,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2016.3.jns152693","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}